Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

Commercial Biosimilars

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Deals Business Strategies

One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac

One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.

China Coronavirus COVID-19

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

Asia Pacific Coronavirus COVID-19

With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

Commercial Respiratory

BI India’s First Woman MD May Have To Hit The Ground Running

The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.

India Commercial
See All

Europe

Set Alert for Europe

Latest From Europe

UK Biotech Booms But Will It Ever Produce A Big Player?

Any chance that Kymab would advance to become a fully integrated biopharma has gone with Sanofi's deep pockets turning the heads of investors. Is the UK ever likely to develop its own Amgen or Moderna?

United Kingdom Companies

COVID-19 Could Change Attitudes To Flu, Bolster Xofluza

Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.

Infectious Diseases Approvals

Coronavirus Update: Moderna Vaccine Gets UK Go-Ahead As EU Approval of Oxford/AZ Vaccine Due In Weeks

Moderna’s mRNA COVID-19 vaccine has received an approval from the UK’s MHRA, while AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week.

Coronavirus COVID-19 Vaccines

CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’

While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.

Companies Commercial

Coronavirus Update: Moderna Secures Third Approval In Israel, World Leader In COVID-19 Vaccinations

Moderna has just secured its third global authorization for its COVID-19 vaccination in Israel, while the European Medicines Agency's review has been delayed.

Coronavirus COVID-19 Companies

Roche's Phesgo Could Reduce Healthcare Costs In EU

Roche’s Phesgo may lower healthcare costs in Europe for treating breast cancer following its approval by European Commission. Other just-approved products nearing the EU market are ViiV’s Vocabria, to be used with Janssen’s Rekambys/Edurant, as a long-acting injectable HIV therapy, and Aimmune’s peanut allergy therapy, Palforzia.

Cancer Market Intelligence
See All

United States

Set Alert for United States

Latest From United States

Stockwatch: New Year, New Politics; Same Old Pricing And Generic Challenges

A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.

Pricing Debate Sales & Earnings

GC LabCell Taps Alliances In Bid For Lead NK Cell Position

After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.

Regenerative Medicine Cancer

Audentes Set To Resume XLMTM Trial As US Hold Lifts

Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.

Gene Therapy Clinical Trials

Indian Companies Find US Partners For COVID-19 Vaccines

Serum Institute has struck a partnership with Dynavax and Aurobindo Pharma with US-based company COVAXX for new vaccine candidates while Bharat Biotech has tied up with Ocugen to explore marketing of its existing contender, Covaxin, in the US.

Commercial Coronavirus COVID-19

US Slashes Import Ban In Daewoong, Medytox Botulinum War

The USITC has issued a final determination in the long-running botulinum toxin dispute between Daewoong and Medytox, sharply cutting the length of Daewoong’s product import ban and reversing its initial decision with respect to Medytox’s bacterial strain. But the dispute seems poised to continue as Daewoong vows further legal steps.

Biologics Legal Issues

The Pfizer Effect: Moderna Tries To Escape Big Pharma’s Shadow At US FDA Vaccines Panel

Sponsor and agency sought to proactively address questions about the potential for anaphylactic reactions with the COVID-19 vaccine given the early real-world experience with Pfizer’s inoculation, which is also uses mRNA technology.

Advisory Committees Coronavirus COVID-19
See All
UsernamePublicRestriction

Register